Clinical Trial Results: A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating guselkumab and golimumab combination therapy in active psoriatic arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Golimumab (golimumab)
• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 2 | Status: COMPLETED | Results posted: 2026-07-23